The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide
Open accessAbstract
AIM: Off-label intravitreal injections of bevacizumab (Avastin) have been given for the treatment of neovascular and exudative ocular diseases since May 2005. Since then, the use of intravitreal bevacizumab has spread worldwide, but the drug-related adverse events associated with its use have been reported only in a few retrospective reviews. The International Intravitreal Bevacizumab Safety Survey was initiated to gather timely information regarding adverse events from doctors around the world via the internet. METHODS: An internet-based survey was designed to identify adverse events associated with intravitreal bevacizumab treatment. The survey web address was disseminated to the international vitreoretinal community via email. Rates of adverse events were calculated from participant responses. RESULTS: 70 centres from 12 countries reported on 7113 injections given to 5228 patients. Doctor-reported adverse events included corneal abrasion, lens injury, endophthalmitis, retinal detachment, inflammation or uveitis, cataract progression, acute vision loss, central retinal artery occlusion, subretinal haemorrhage, retinal pigment epithelium tears, blood pressure elevation, transient ischaemic attack, cerebrovascular accident and death. None of the adverse event rates exceeded 0.21%. CONCLUSION: Intravitreal bevacizumab is being used globally for ocular diseases. Self-reporting of adverse events after intravitreal bevacizumab injections did not show an increased rate of potential drug-related ocular or systemic events. These short-term results suggest that intravitreal bevacizumab seems to be safe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Rosenfeld, P. J., Moshfeghi, A. A., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-14 · Cited by 904
Self-citationMICHELS, S., ROSENFELD, P., PULIAFITO, C., MARCUS, E., & VENKATRAMAN, A. (2005) · Ophthalmology · doi:10.1016/j.ophtha.2005.02.007 · Cited by 664
Self-citationSPAIDE, R. F., LAUD, K., FINE, H. F., KLANCNIK, J. M., MEYERLE, C. B., YANNUZZI, L. A., SORENSON, J., SLAKTER, J., FISHER, Y. L., & COONEY, M. J. (2006) · Retina · doi:10.1097/00006982-200604000-00001 · Cited by 630
RISKS OF INTRAVITREOUS INJECTION: A COMPREHENSIVE REVIEW
JAGER, R. D., AIELLO, L. P., PATEL, S. C., & CUNNINGHAM, E. T. (2004) · Retina · doi:10.1097/00006982-200410000-00002 · Cited by 572
SPAIDE, R. F., & FISHER, Y. L. (2006) · Retina · doi:10.1097/00006982-200603000-00004 · Cited by 507
Rosenfeld, P. J., Fung, A. E., & Puliafito, C. A. (2005) · Ophthalmic Surgery, Lasers and Imaging Retina · doi:10.3928/1542-8877-20050701-15 · Cited by 489
Self-citationRICH, R. M., ROSENFELD, P. J., PULIAFITO, C. A., DUBOVY, S. R., DAVIS, J. L., FLYNN, H. W., GONZALEZ, S., FEUER, W. J., LIN, R. C., LALWANI, G. A., et al. (2006) · Retina · doi:10.1097/01.iae.0000225766.75009.3a · Cited by 484
Self-citationITURRALDE, D., SPAIDE, R. F., MEYERLE, C. B., KLANCNIK, J. M., YANNUZZI, L. A., FISHER, Y. L., SORENSON, J., SLAKTER, J. S., FREUND, K. B., COONEY, M., et al. (2006) · Retina · doi:10.1097/00006982-200603000-00005 · Cited by 460
Ranibizumab for Treatment of Neovascular Age-Related Macular Degeneration
Heier, J. S., Antoszyk, A. N., Pavan, P. R., Leff, S. R., Rosenfeld, P. J., Ciulla, T. A., Dreyer, R. F., Gentile, R. C., Sy, J. P., Hantsbarger, G., et al. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.10.052 · Cited by 360
Self-citationSHAHAR, J., AVERY, R. L., HEILWEIL, G., BARAK, A., ZEMEL, E., LEWIS, G. P., JOHNSON, P. T., FISHER, S. K., PERLMAN, I., & LOEWENSTEIN, A. (2006) · Retina · doi:10.1097/00006982-200603000-00002 · Cited by 350
REGRESSION OF RETINAL AND IRIS NEOVASCULARIZATION AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT
AVERY, R. L. (2006) · Retina · doi:10.1097/00006982-200603000-00016 · Cited by 342
Voluntary Anonymous Reporting of Medical Errors for Neonatal Intensive Care
Suresh, G., Horbar, J. D., Plsek, P., Gray, J., Edwards, W. H., Shiono, P. H., Ursprung, R., Nickerson, J., Lucey, J. F., Goldmann, D., et al. (2004) · Pediatrics · doi:10.1542/peds.113.6.1609 · Cited by 335
Patient Online Self-Reporting of Toxicity Symptoms During Chemotherapy
Basch, E., Artz, D., Dulko, D., Scher, K., Sabbatini, P., Hensley, M., Mitra, N., Speakman, J., McCabe, M., & Schrag, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.275 · Cited by 310
TESTING INTRAVITREAL TOXICITY OF BEVACIZUMAB (AVASTIN)
MANZANO, R. P. A., PEYMAN, G. A., KHAN, P., & KIVILCIM, M. (2006) · Retina · doi:10.1097/00006982-200603000-00001 · Cited by 305
ELECTROPHYSIOLOGIC FINDINGS AFTER INTRAVITREAL BEVACIZUMAB (AVASTIN) TREATMENT
Maturi, R. K., Bleau, L., & Wilson, D. L. (2006) · Retina · doi:10.1097/00006982-200603000-00003 · Cited by 157
Intravitreal Bevacizumab in a Patient With Neovascular Glaucoma
Kahook, M. Y., Schuman, J. S., & Noecker, R. J. (2006) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/1542-8877-20060301-11 · Cited by 137
Luthra, S., Narayanan, R., Marques, L. E. A., Chwa, M., Kim, D., Dong, J., Seigel, G. M., Neekhra, A., Gramajo, A. L., BROWN, D. J., et al. (2006) · Retina · doi:10.1097/01.iae.0000222547.35820.52 · Cited by 120
Patient online self-reporting of toxicity symptoms during chemotherapy
Basch, E., Dulko, D., Artz, D. R., Scher, K. S., Sabbatini, P. J., Hensley, M., Mitra, N., Speakman, J., McCabe, M. S., & Schrag, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.6025 · Cited by 11
Cited by
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
Wu, L., Martínez-Castellanos, M. A., Quiroz-Mercado, H., Arevalo, J. F., Berrocal, M. H., Farah, M. E., Maia, M., Roca, J. A., Rodriguez, F. J., & for the Pan American Collaborative Retina Group (PACORES) (2007) · Graefe's Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-007-0660-z · Cited by 456
Corneal Neovascularization: An Anti-VEGF Therapy Review
Chang, J.-H., Garg, N. K., Lunde, E., Han, K.-Y., Jain, S., & Azar, D. T. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.007 · Cited by 381
Sato, T., Wada, K., Arahori, H., Kuno, N., Imoto, K., Iwahashi-Shima, C., & Kusaka, S. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.07.005 · Cited by 327
Metadata
- Authors
- Fung, A. E., Rosenfeld, P. J., & Reichel, E.
- Venue
- British Journal of Ophthalmology
- Publisher
- BMJ
- Published
- 2006-11-01
- Volume
- 90
- Issue
- 11
- Pages
- 1344-1349
- ISSN
- 0007-1161 (ISSN-L)
- OpenAlex
- W2039446733
- Cited by
- 532
- References
- 20
- FWCI
- 53.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.